eptivA Therapeutics Ltd. secured a $150m financing behind the development of neridronate in CRPS.
Public source
Publisher name
Public post
A $150m financing behind the development of neridronate in CRPS is significant. But it’s the clinical development strategy behind it that I find more interesting. Neridr…
Company
eptivA Therapeutics Ltd.
A clinical stage biotech company utilising novel Personalized Analgesics® research to create precision pain medicines
- Industry
- Biotechnology Research
- Location
- Oxford, GB
- Company size
- 2–10 employees
About eptivA Therapeutics Ltd.
Eptiva Therapeutics is a clinical stage Biotech company transforming the way pain is treated with PERSONALIZED ANALGESICS®. We have invented novel in silico research methods to create the first precision medicine approach to pain.
See moreLatest activity
Latest activity from eptivA Therapeutics Ltd.
6 signals
Research & Knowledge
eptivA Therapeutics Ltd. published a new Nature Communications paper by Negm and colleagues examining the spinal circuitry associated with mechanical allodynia after nerve injury using two-photon calcium imaging in an ex vivo mouse somatosensory preparation.
Research & Knowledge
eptivA Therapeutics Ltd. published a new Science paper in 2026 showing that a non-hallucinogenic 5-HT2A agonist produces similar protection in preclinical models.
Research & Knowledge
eptivA Therapeutics Ltd. published a study in PAIN showing that GLP-1 receptor agonists reduce painful diabetic peripheral neuropathy in 10.1% of people with type 2 diabetes compared to standard treatment in 35.1%
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
Gossamer Bio
Gossamer Bio announced up to $250 million in financing to support the program through potential FDA approval.
Capital & Finance
Amyl Therapeutics
Amyl Therapeutics secured an €8.25M Series A extension to validate its novel neurodegenerative disease platform.
Capital & Finance
Korsana Biosciences
Korsana Biosciences closed a $380 million financing round to support its work in the coming years, including through multiple clinical milestones for its lead program KRSA-028.
Capital & Finance
Nxera Pharma
Nxera Pharma received a US$8.6 million milestone payment following late-stage development progress in the selective orexin receptor 2 (OX2R) agonist portfolio originating from its research collaboration with Centessa Pharmaceuticals.
Capital & Finance
EIT Pharma, Inc.